Reprotect Buffergel polyacrylic gel contraceptive's vaginal irritation rate studied by NIAID.
This article was originally published in The Tan Sheet
Executive Summary
BUFFERGEL CONTRACEPTIVE NIAID/HIVNET U.S. PHASE I CLINICAL TRIAL will be completed in September, Buffergel owner Reprotect of Baltimore, Md., said. The company owns the rights to market the polyacrylic acid gel upon which Buffergel is based; the gel was created by company founders Richard Cone, PhD, and Kevin Whaley, PhD, Johns Hopkins University, and Thomas Moench, MD, formerly with Hopkins, now medical director of Reprotect. The National Institute of Allergy & Infectious Diseases, through its HIVNET international HIV research network, is interested in the product as a possible prophylaxis against transmission of human immunodeficiency virus.